Jefferies Downgrades Immunocore Holdings plc (IMCR) to Hold with a $33 Price Target

Core Insights - Immunocore Holdings plc (NASDAQ:IMCR) is recognized as one of the 12 best UK stocks to buy according to hedge funds [1] - Jefferies downgraded Immunocore Holdings plc from Buy to Hold with a price target reduction from $48 to $33, citing a "moderate" total addressable market for its lead product Kimmtrak and emphasizing the risks associated with its pipeline [2] - The company reported a fourth-quarter EPS of (60 cents), which was below the consensus estimate of (20 cents), and revenue of $104.5 million, slightly below the consensus of $107.77 million [2] - CEO Bahija Jallal highlighted a productive year in 2025 with $400 million in Kimmtrak sales and plans for 2026 focused on executing clinical trials, including key data expected in oncology and the initiation of its first autoimmune study [2] Company Overview - Immunocore Holdings plc specializes in developing and commercializing immunomodulating therapies aimed at treating cancer, infectious diseases, and autoimmune conditions [3]